Apparition - We understand your views on who is "paying/sponsoring" the trial and the frustration with not having more "meaty" data updates during the trial. That said, if you think a sponsoring company like Cellceutix can waltz in to DF, one of the pre-eminent cancer research institutions in the world and demand to have an unfettered say in what gets released and when, then I believe you are very mistaken. DF would respectfully say to the sponsoring company - there is the door, our reputation, knowledge about how a trial should be designed and run (thousands of trials) and desire to do get it right, comes first. It's my opinion the info clamp down came after the R&R 2013 powerpoint presentation revealed so much about the initial cohort results, including the tumor reduction/stabilization and P21 expression at 20-30 mg dosage. I think DF had a pow wow with Menon/Erlich and it was mutually agreed there would be no more detailed info released until the end of the study, just cohort progression, dose etc. but not the same level of detail. Too much at stake. So while Cellceutix is sponsoring, it's strongly my opinion DF definitely has a say and what is made public during the trial. I think it was a real "come to Jesus" meeting and its been a much tighter ship since then. Just my opinion, DF is arguably the best at running oncology trials and I believe they definitely have a say in what is going to be released and when. Hopefully cohort progression news on the big K in coming weeks followed by good Brilicidin results. I think brilicidin can be a gold mine, drug resistant bacteria strains are just going to get worse, we a re in the right spot at the right time....
